Trial Profile
Phase II Combination Immunotherapy After ASCT for Advanced Myeloma to Study MAGE-A3 Immunizations With Hiltonol (Poly-ICLC) Plus Transfer of Vaccine-Primed Autologous T Cells Followed by Lenalidomide Maintenance
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Biropepimut-S (Primary) ; Lenalidomide; Pneumococcal 7-valent CRM197 vaccine conjugate; Poly ICLC
- Indications Myeloma
- Focus Therapeutic Use
- 17 Dec 2018 Status changed from active, no longer recruiting to completed.
- 18 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.
- 18 Dec 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Jun 2018.